title: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation.
abstract: Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) may provide an alternative therapy for young patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (sAML) lacking a suitable donor. We report the results for 79 patients with MDS/sAML transplanted with autologous marrow in first complete remission (CR). Within the total group of 79, a cohort of 55 patients for whom the duration of first CR was known were compared with a matched control group of 110 patients with de novo AML. The 2-year survival, disease-free survival (DFS), and relapse rates for the 79 patients transplanted in first CR were 39%, 34%, and 64%, respectively. The relapse risk was greater than 55% for all stages and all disease categories. Patients younger than 40 years had a significantly (P = .04) better DFS (39%) than patients older than 40 years (25%). The DFS at 2 years was 28% for the cohort of 55 patients transplanted for MDS/sAML and 51% for those transplanted for de novo AML (P = .025). Relapse rates were 69% for patients with MDS/sAML and 40% for those with de novo AML (P = .007). ABMT for MDS or secondary leukemia results in a lower DFS when compared with similarly treated patients with de novo AML due to a higher relapse rate. The DFS of 28% for these patients suggests that autotransplantation may be a valuable therapy for this disease. The low treatment-related mortality rate of less than 10% supports the view that sufficient numbers of hematopoietic stem cells are present in patients with MDS to allow adequate repopulation after autologous stem-cell transplantation.
authors.affiliation: Department of Hematology, University Hospital Nijmegen, Nijmegen, The Netherlands.
authors.forename: T
authors.initials: T
authors.lastname: De Witte
authors.forename: A
authors.initials: A
authors.lastname: Van Biezen
authors.forename: J
authors.initials: J
authors.lastname: Hermans
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.forename: V
authors.initials: V
authors.lastname: Runde
authors.forename: R
authors.initials: R
authors.lastname: Or
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: S B
authors.initials: SB
authors.lastname: Mauri
authors.forename: A
authors.initials: A
authors.lastname: Carella
authors.forename: J
authors.initials: J
authors.lastname: Apperley
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: J P
authors.initials: JP
authors.lastname: Laporte
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D016019:Survival Analysis; D014182:Transplantation, Autologous